hh.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
A Perspective on Oral Immunotherapeutic Tools and Strategies for Autoimmune Disorders
Texas Tech University, Lubbock, TX, United States.ORCID iD: 0000-0002-8907-7009
Raniganj Girls College, Bardhaman, India.
Halmstad University, School of Business, Innovation and Sustainability.ORCID iD: 0000-0001-7790-8197
2023 (English)In: Vaccines, E-ISSN 2076-393X, Vol. 11, no 6, article id 1031Article, review/survey (Refereed) Published
Abstract [en]

Oral immune tolerance is a physiological process to achieve tolerance against autoimmunity by oral ingestion of self-antigen(s) or other therapeutics. At the cellular level, oral tolerance suppresses autoimmune diseases by activating FoxP-positive and -negative regulatory T cells (Tregs) and/or causing clonal anergy or deletion of autoreactive T cells, affecting B cell tolerance. However, oral delivery of antigens/biologics is challenging due to their instability in the harsh environment of the gastrointestinal (GI) tract. Several antigen/drug delivery tools and approaches, including micro/nanoparticles and transgenic plant-based delivery systems, have been explored to demonstrate oral immune tolerance for different autoimmune diseases successfully. However, despite the effectiveness, variation in results, dose optimization, and undesirable immune system activation are the limitations of the oral approach to further advancement. From this perspective, the current review discusses the oral tolerance phenomenon, cellular mechanisms, antigen delivery tools and strategies, and its challenges. © 2023 by the authors.

Place, publisher, year, edition, pages
Basel: MDPI, 2023. Vol. 11, no 6, article id 1031
Keywords [en]
antigen delivery system, autoimmune diseases, nanoparticles, oral route, rheumatoid arthritis, transgenic plants, type 1 diabetes
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:hh:diva-51435DOI: 10.3390/vaccines11061031ISI: 001015857000001PubMedID: 37376420Scopus ID: 2-s2.0-85163580304OAI: oai:DiVA.org:hh-51435DiVA, id: diva2:1788865
Available from: 2023-08-17 Created: 2023-08-17 Last updated: 2025-02-18Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Nandakumar, Kutty Selva

Search in DiVA

By author/editor
Shakya, Akhilesh KumarNandakumar, Kutty Selva
By organisation
School of Business, Innovation and Sustainability
In the same journal
Vaccines
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 44 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf